Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2019-07-18 Interim / Quarterly Rep…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Hansa Biopharma for the second quarter of 2019. It includes a summary of financial performance, a detailed table of financial data (Nettoomsättning, Rörelseresultat, etc.), a CEO statement, and updates on clinical trials and regulatory progress. It contains substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report. Q2 2019
2019-07-18 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – JUNE 2019' and contains comprehensive financial statements, including income statements, cash flow data, and balance sheet metrics for the second quarter and first half of 2019. It also includes detailed management commentary on business operations, clinical trial progress, and strategic outlook. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2019
2019-07-18 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for 'Invesco Ltd.' in 'Hansa Biopharma AB'. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and voting rights percentages, culminating in a 'Resulting distribution of total holdings'. The presence of specific share quantities, percentages crossing a threshold (implied by the structure, though the initial holding was 0), and the mention of 'Reason for major shareholding notification' strongly indicates a filing related to significant ownership changes. This aligns perfectly with the definition of Major Shareholding Notification (MRQ). The document is a direct notification of the holding change, not an announcement of a report (RPA) or a general regulatory filing (RNS).
2019-05-27 English
Kommuniké från årsstämma i Hansa Biopharma AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kommuniké från årsstämma i Hansa Biopharma AB (publ)" which translates to "Communiqué from the Annual General Meeting (AGM) in Hansa Biopharma AB (publ)". It details the resolutions passed at the AGM held on May 22, 2019, including the approval of financial statements, election of the board and auditor, remuneration decisions, and approval of incentive programs (LTIP 2019 and Optionsprogrammet 2019). This content directly relates to the formal proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2019-05-22 Swedish
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled 'Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)' and details resolutions passed at this meeting, such as the adoption of financial statements, election of the Board of Directors and auditor, and approval of incentive programs (LTIP 2019, Option Programme 2019). These are the core components of an AGM outcome report. Therefore, the classification is AGM-R (AGM Information). The document length is substantial (8186 chars), confirming it is the report itself, not just an announcement of the report (RPA).
2019-05-22 English
Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress
Report Publication Announcement Classification · 99% confidence The document is titled "Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress" and details specific presentations, dates, and speakers related to their drug IDEFIRIXTM at a medical conference (ATC). This type of announcement, focusing on scientific data presentation at an industry event, is characteristic of investor or scientific updates, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is an announcement about scientific data being presented, it fits best under Investor Presentation (IP) if it were the presentation itself, or a general Regulatory Filing (RNS) if it's just a press release about the event. Given the content is a press release announcing future scientific presentations, it is most closely aligned with providing information to investors about ongoing research milestones, making 'Investor Presentation' (IP) a strong candidate, although 'Regulatory Filings' (RNS) is a common bucket for press releases. However, since the content is specifically about presentations of clinical data, which is a key component of investor communication regarding R&D progress, I will classify it as an Investor Presentation (IP) as it is a direct communication about the content to be shared with investors/the public at a conference, rather than a general regulatory notice.
2019-05-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.